<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tenecteplase: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tenecteplase: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tenecteplase: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11075" href="/d/html/11075.html" rel="external">see "Tenecteplase: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F228480"><span class="drugH1">Brand Names: US</span>
<ul>
<li>TNKase</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868435"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>TNKase</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F228508"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Thrombolytic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F228484"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ff0f5df-dba4-4340-926f-01002ca870e3">Acute ischemic stroke</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute ischemic stroke (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Perform non–contrast-enhanced CT or MRI prior to administration. After ensuring eligibility criteria are met, administer within 4.5 hours of symptom onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29694815','lexi-content-ref-28780236','lexi-content-ref-35779553']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29694815','lexi-content-ref-28780236','lexi-content-ref-35779553'])">Ref</a></span>). Symptom onset is usually defined as the time last seen normal or at baseline; however, some stroke centers use imaging-based criteria for select patients who have unknown time of symptom onset (eg, wake-up or unwitnessed stroke) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27965285','lexi-content-ref-Filho.2020a','lexi-content-ref-31892636']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27965285','lexi-content-ref-Filho.2020a','lexi-content-ref-31892636'])">Ref</a></span>). Before starting antiplatelet agents or anticoagulation, wait 24 hours after tenecteplase administration and confirm stroke is stable with no evidence of hemorrhage via a follow-up non-contrast CT (or MRI). The risk of administering antiplatelet or anticoagulant therapy within 24 hours after tenecteplase is uncertain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31662037','lexi-content-ref-Filho.2020b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31662037','lexi-content-ref-Filho.2020b'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 0.25 mg/kg (maximum total dose: 25 mg) once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31662037','lexi-content-ref-29694815','lexi-content-ref-32078683','lexi-content-ref-35779553']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31662037','lexi-content-ref-29694815','lexi-content-ref-32078683','lexi-content-ref-35779553'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5e88e68-0382-41ec-84f2-f140e6539947">Pulmonary embolism, acute, hemodynamically stable, intermediate to high risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary embolism, acute, hemodynamically stable, intermediate to high risk (submassive) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For most patients without hypotension, parenteral or oral anticoagulation alone is preferred over thrombolysis and anticoagulation. Systemic thrombolysis may be considered for select, younger patients with low risk of bleeding who deteriorate (eg, progressive increase in heart rate, decrease in BP, signs of shock, worsening gas exchange, progressive right heart dysfunction on echocardiography, increase in cardiac biomarkers) despite parenteral anticoagulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34352278','lexi-content-ref-33007077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34352278','lexi-content-ref-33007077'])">Ref</a></span>). Some experts prefer catheter-directed therapy (CDT) if the expertise is available and the patient has a low risk of bleeding; or may consider CDT over systemic in patients with an increased risk of bleeding or with contraindications to systemic thrombolytic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Weinberg.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Weinberg.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Administer dose as a single bolus over 5 to 10 seconds (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24484241','lexi-content-ref-24716681']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24484241','lexi-content-ref-24716681'])">Ref</a></span>). Institute or resume parenteral anticoagulation following thrombolytic administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33007077','lexi-content-ref-31504429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33007077','lexi-content-ref-31504429'])">Ref</a></span>). Some experts start parenteral anticoagulation following thrombolytic administration when aPTT is less than twice its ULN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Weinberg.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Weinberg.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;60 kg: 30 mg</p>
<p style="text-indent:-2em;margin-left:6em;">≥60 to &lt;70 kg: 35 mg</p>
<p style="text-indent:-2em;margin-left:6em;">≥70 to &lt;80 kg: 40 mg</p>
<p style="text-indent:-2em;margin-left:6em;">≥80 to &lt;90 kg: 45 mg</p>
<p style="text-indent:-2em;margin-left:6em;">≥90 kg: 50 mg</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="83eeaef5-04fe-4d5c-9bb5-eecc043e935c">Pulmonary embolism, acute, hemodynamically unstable, high risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary embolism, acute, hemodynamically unstable, high risk (massive) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consider systemic thrombolytic therapy followed by anticoagulation over anticoagulation alone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34352278','lexi-content-ref-33007077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34352278','lexi-content-ref-33007077'])">Ref</a></span>). Systemic thrombolysis is generally preferred over CDT since systemic treatment can be completed more rapidly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34352278','lexi-content-ref-33007077','lexi-content-ref-Weinberg.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34352278','lexi-content-ref-33007077','lexi-content-ref-Weinberg.1'])">Ref</a></span>). Some experts prefer CDT, when expertise is available, if systemic thrombolytic is contraindicated or in patients with an increased bleeding risk or persistent hemodynamic instability despite systemic thrombolysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Weinberg.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Weinberg.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Administer dose as a single bolus over 5 to 10 seconds (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17221330','lexi-content-ref-15744554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17221330','lexi-content-ref-15744554'])">Ref</a></span>). Institute or resume parenteral anticoagulation following thrombolytic administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33007077','lexi-content-ref-31504429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33007077','lexi-content-ref-31504429'])">Ref</a></span>). Some experts start parenteral anticoagulation following thrombolytic administration when aPTT is less than twice its ULN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Weinberg.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Weinberg.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;60 kg: 30 mg</p>
<p style="text-indent:-2em;margin-left:6em;">≥60 to &lt;70 kg: 35 mg</p>
<p style="text-indent:-2em;margin-left:6em;">≥70 to &lt;80 kg: 40 mg</p>
<p style="text-indent:-2em;margin-left:6em;">≥80 to &lt;90 kg: 45 mg</p>
<p style="text-indent:-2em;margin-left:6em;">≥90 kg: 50 mg</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c221423b-d38e-4b98-909f-fb0bab87ad27">Pulmonary embolism associated with cardiac arrest</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary embolism associated with cardiac arrest (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Thrombolytic therapy is not recommended for routine use during cardiopulmonary arrest. May consider on a case-by-case basis (eg, suspected PE-induced cardiac arrest) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33081529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33081529'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Administer as a single bolus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19092151','lexi-content-ref-16563599']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19092151','lexi-content-ref-16563599'])">Ref</a></span>). Use therapeutic IV anticoagulation in addition to thrombolytic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26472998','lexi-content-ref-31504429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26472998','lexi-content-ref-31504429'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;60 kg: 30 mg</p>
<p style="text-indent:-2em;margin-left:6em;">≥60 to &lt;70 kg: 35 mg</p>
<p style="text-indent:-2em;margin-left:6em;">≥70 to &lt;80 kg: 40 mg</p>
<p style="text-indent:-2em;margin-left:6em;">≥80 to &lt;90 kg: 45 mg</p>
<p style="text-indent:-2em;margin-left:6em;">≥90 kg: 50 mg</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ce597fa8-5ccb-4a8a-9703-dd1309dbd989">ST-elevation myocardial infarction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>ST-elevation myocardial infarction:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>: Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy. Thrombolytic therapy is an option in centers that do not have PCI capability, followed by transfer to a PCI capable center. Administer thrombolytic therapy within 30 minutes of first medical contact (in ambulance or emergency department) if primary PCI cannot be performed within 120 minutes; if primary PCI is not available, may still consider thrombolysis in patients who present late (within 12 to 24 hours of symptom onset) and have ongoing ischemia or extensive ST elevation. Administer aspirin, clopidogrel, and anticoagulant therapy (ie, unfractionated heparin, enoxaparin, or fondaparinux) in combination with thrombolytic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304','lexi-content-ref-28886621']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304','lexi-content-ref-28886621'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Administer as a single bolus over 5 seconds:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;60 kg: 30 mg</p>
<p style="text-indent:-2em;margin-left:6em;">≥60 to &lt;70 kg: 35 mg</p>
<p style="text-indent:-2em;margin-left:6em;">≥70 to &lt;80 kg: 40 mg</p>
<p style="text-indent:-2em;margin-left:6em;">≥80 to &lt;90 kg: 45 mg</p>
<p style="text-indent:-2em;margin-left:6em;">≥90 kg: 50 mg</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991292"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Dialyzable: Unknown, but unlikely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26714677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26714677'])">Ref</a></span>)</p></div>
<div class="block doha drugH1Div" id="F50988609"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: No dosage adjustment provided in manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: No dosage adjustment provided in manufacturer's labeling; weigh the risk of bleeding against the benefits with tenecteplase especially in those with a coagulopathy.</p></div>
<div class="block doe drugH1Div" id="F228485"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Although dosage adjustments are not recommended, elderly patients have a higher incidence of morbidity and mortality with use of thrombolytics.</p></div>
<div class="block adr drugH1Div" id="F228456"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Cardiovascular: Heart failure (12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Cardiovascular: Cardiogenic shock (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Immunologic: Antibody development</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hypersensitivity: Hypersensitivity reaction (including anaphylaxis and angioedema)</p></div>
<div class="block coi drugH1Div" id="F228469"><span class="drugH1">Contraindications</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Tenecteplase Indication-Specific Contraindications</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><tfoot valign="top">
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">
<sup>a</sup> STEMI = ST-elevation myocardial infarction; AIS = acute ischemic stroke; LMWH = low-molecular-weight heparin.</p></td></tr>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">
<sup>b</sup> Thrombolysis may be administered to patients presenting with initial blood glucose concentrations &lt;50 that are subsequently normalized (Oliveira-Filho 2023).</p></td></tr>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">
<sup>c</sup> Patients without a history of thrombocytopenia or suspicion of bleeding diathesis, recent use of oral anticoagulants, or recent use of heparin may receive thrombolysis prior to availability of these laboratory results. Discontinue thrombolysis if platelets &lt;100,000/mm<sup>3</sup>, INR &gt;1.7, aPTT &gt;40 seconds, or PT &gt;15 seconds (Oliveira-Filho 2023).</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">
<b>Treatment of STEMI<sup>a</sup></b></p></td>
<td align="left">
<p style="text-indent:0em;">Active internal bleeding; history of cerebrovascular accident (additional guidance provided by ACCF/AHA [O’Gara 2013]); recent (within 2 months) intracranial/intraspinal surgery or trauma; intracranial neoplasm, arteriovenous malformation or aneurysm; known bleeding diathesis; severe uncontrolled hypertension (additional guidance provided by ACCF/AHA [O’Gara 2013]).</p>
<p style="text-indent:0em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to tenecteplase or any component of the formulation.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<i>Additional recommended contraindications (ACCF/AHA [O'Gara 2013</i>
<i>]):</i> Ischemic stroke within 3 months; prior intracranial hemorrhage; active bleeding (excluding menses); suspected aortic dissection; significant closed head or facial trauma within 3 months; severe uncontrolled hypertension (unresponsive to emergency therapy).</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>Treatment of AIS<sup>a</sup> (off label)</b></p></td>
<td align="left">
<p style="text-indent:0em;">Intracranial hemorrhage (history of or current); subarachnoid hemorrhage (suspicion of or confirmed); active internal bleeding; recent (within 3 months) intracranial or intraspinal surgery, ischemic stroke, or severe head trauma; known bleeding diathesis; GI malignancy or bleed within previous 21 days; persistent BP &gt;185 mm Hg systolic or &gt;110 mm Hg diastolic; CT scan showing extensive regions of obvious hypodensity consistent with irreversible injury; symptoms consistent with infective endocarditis; AIS symptoms known or suspected to be associated with aortic arch dissection; intra-axial intracranial neoplasm; blood glucose concentration &lt;50 mg/dL<sup>b</sup>; coagulopathy (platelets &lt;100,000/mm<sup>3</sup>, INR &gt;1.7, aPTT &gt;40 seconds, or PT &gt;15 seconds)<sup>c</sup>; current use (eg, within previous 48 hours) of oral anticoagulants with an INR &gt;1.7 or PT &gt;15 seconds, current use of direct factor Xa or thrombin inhibitors with evidence of anticoagulant effect demonstrated by laboratory test results (eg, aPTT, INR, platelets, ecarin clotting time, thrombin time, appropriate anti-factor Xa assay); administration of full treatment dose LMWH<sup>a</sup> within previous 24 hours (Haley 2010; Oliveira-Filho 2023).</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>Treatment of pulmonary embolism (off label)</b></p></td>
<td align="left">
<p style="text-indent:0em;">Structural intracranial disease, previous intracranial hemorrhage, ischemic stroke within 3 months, active bleeding, recent brain or spinal surgery, recent head trauma with fracture or brain injury, bleeding diathesis.</p></td></tr></tbody></table></div>
<div class="block war drugH1Div" id="F228453"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Arrhythmias: Coronary thrombolysis may result in reperfusion arrhythmias (eg, sinus bradycardia, accelerated idioventricular rhythm, ventricular premature depolarizations, ventricular tachycardia). Antiarrhythmic therapy should be available during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding: Internal bleeding (intracranial, retroperitoneal, gastrointestinal, genitourinary, respiratory) or external bleeding (especially at arterial and venous puncture sites) may occur (may be fatal). Monitor all potential bleeding sites; if serious bleeding occurs, the infusion of tenecteplase and any other concurrent anticoagulants (eg, heparin) and antiplatelets should be stopped and the patient should be treated appropriately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cholesterol embolization: Cholesterol embolization has been reported in patients treated with thrombolytic agents; may present as livedo reticularis, "purple toe" syndrome, acute renal failure, gangrenous digits, hypertension, pancreatitis, myocardial infarction, cerebral infarction, spinal cord infarction, retinal artery occlusion, bowel infarction, or rhabdomyolysis and can be fatal.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions (eg, anaphylaxis, urticaria, angioedema, laryngeal edema, rash) have been reported after administration. Monitor closely for hypersensitivity reactions during infusion and for several hours after; initiate appropriate therapy if symptoms of hypersensitivity occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic events: Use may increase risk of thromboembolic events in patients with high probability of left heart thrombus (eg, patients with mitral stenosis or atrial fibrillation).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Conditions that increase bleeding risk: For the following conditions, the risk of bleeding is higher with use of thrombolytics and should be weighed against the benefits of therapy:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• Acute ischemic stroke</i>: Serious trauma or major surgery in previous 14 days, history of gastrointestinal bleeding (remote) or genitourinary bleeding, seizure at stroke onset with postictal neurologic impairment, arterial puncture at noncompressible site in previous 7 days, intracranial aneurysm (eg, large [≥10 mm], untreated, unruptured), intracranial vascular malformation (untreated) (Oliveira-Filho 2023). While guidelines recommend against thrombolysis in patients presenting with a mild nondisabling stroke (NIH 0 to 5), some experts suggest patients with a persistent neurologic deficit that is potentially disabling, even in the context of improvement, should receive IV thrombolysis if otherwise eligible (AHA/ASA [Powers 2019], Oliveira-Filho 2023).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• PE: </i>Systolic BP &gt;180 mm Hg or diastolic BP &gt;110 mm Hg; recent bleeding (nonintracranial); recent surgery or invasive procedure; ischemic stroke &gt;3 months previously; anticoagulated (eg, VKA therapy); traumatic CPR; pericarditis or pericardial fluid; diabetic retinopathy; age &gt;75 years; low body weight (&lt;60 kg); female; black (Kearon 2012; Kearon 2016); lumbar puncture within 10 days (ASRA [Horlocker 2012]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• STEMI: </i>History of chronic, severe, poorly controlled hypertension; significant hypertension on presentation (systolic BP &gt;180 mm Hg or diastolic BP &gt;110 mm Hg); history of prior ischemic stroke &gt;3 months; dementia; traumatic or prolonged CPR (&gt;10 minutes); major surgery (&lt;3 weeks); recent internal bleeding (within 2 to 4 weeks); noncompressible vascular punctures; active peptic ulcer; oral anticoagulant therapy (ACC/AHA [O’Gara 2013]); lumbar puncture within 10 days (ASRA [Horlocker 2012]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in patients with advanced age; increased risk of bleeding. The 30-day mortality in the ASSENT-2 trial of AMI patients was 2.5% for patients &lt;65 years of age, 8.5% for patients 65 to 74 years, and 16.2% for patients ≥75 years. The intracranial hemorrhage rate was 0.4% for patients &lt;65 years, 1.6% for patients 65 to 74 years, and 1.7% for patients ≥75 years. The risks and benefits of use should be weighed carefully in the elderly.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Avoid intramuscular injections and nonessential handling of the patient for a few hours after administration. Venipunctures should be performed carefully and only when necessary. If arterial puncture is necessary, use an upper extremity vessel that can be manually compressed. Caution with readministration of tenecteplase.</p></div>
<div class="block foc drugH1Div" id="F228464"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">TNKase: 50 mg</p></div>
<div class="block geq drugH1Div" id="F228449"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F23613417"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (TNKase Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $9,119.53</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868436"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">TNKase: 50 mg</p></div>
<div class="block adm drugH1Div" id="F228466"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Tenecteplase is <b>incompatible</b> with dextrose solutions. Dextrose-containing lines must be flushed with a saline solution before and after administration. Administer as a single IV bolus over 5 seconds. Avoid IM injections and nonessential handling of patient.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>PE, acute (off-label use):</i> Administer as an IV bolus over 5 to 10 seconds using a peripheral vein (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315268','lexi-content-ref-26867832']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315268','lexi-content-ref-26867832'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F228465"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>ST-elevation myocardial infarction:</b> Management of ST-elevation myocardial infarction for the lysis of thrombi in the coronary vasculature to restore perfusion and reduce mortality.</p></div>
<div class="block off-label drugH1Div" id="F50579961"><span class="drugH1">Use: Off-Label: Adult</span><p>Acute ischemic stroke; Pulmonary embolism, acute, hemodynamically unstable, high risk (massive); Pulmonary embolism, acute, hemodynamically stable, intermediate to high risk (submassive); Pulmonary embolism associated with cardiac arrest</p></div>
<div class="block mst drugH1Div" id="F228516"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">TNKase may be confused with Activase, t-PA</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">TNK (occasional abbreviation for TNKase) is an error-prone abbreviation (mistaken as TPA or TXA, error-prone abbreviation for tranexamic acid)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (IV) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300111"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F228458"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Thrombolytic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.  Management: Monitor for signs and symptoms of bleeding if these agents are combined. For the treatment of acute ischemic stroke, avoidance with anticoagulants is often recommended, see full drug interaction monograph for details.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprotinin: May diminish the therapeutic effect of Thrombolytic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Thrombolytic Agents may enhance the anticoagulant effect of Dabigatran Etexilate.  Management: Carefully monitor for bleeding.  Dabigatran Canadian labeling recommends avoiding use with thrombolytic agents. Consider avoiding alteplase treatment of acute ischemic stroke in patients receiving dabigatran (see full drug monograph for details).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Defibrotide: May enhance the adverse/toxic effect of Thrombolytic Agents. Specifically, the risk of hemorrhage may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desirudin: Thrombolytic Agents may enhance the anticoagulant effect of Desirudin.  Management: Discontinue treatment with thrombolytic agents prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Thrombolytic Agents. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Thrombolytic Agents. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the adverse/toxic effect of Thrombolytic Agents. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: Thrombolytic Agents may enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protein C Concentrate (Human): May enhance the adverse/toxic effect of Thrombolytic Agents. Specifically, the risk of bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tranexamic Acid: May diminish the therapeutic effect of Thrombolytic Agents. Thrombolytic Agents may diminish the therapeutic effect of Tranexamic Acid.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F228471"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Bleeding may occur with tenecteplase therapy and the risk of bleeding complications may be increased in pregnant patients; however, use may be considered if other treatment options are not feasible or appropriate (Alameh 2021; ESC [Regitz-Zagrosek 2018]; Ismail 2017; Merlo 2022).</p></div>
<div class="block brc drugH1Div" id="F17916902"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if tenecteplase is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F228462"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC, aPTT, signs and symptoms of bleeding, ECG monitoring</p></div>
<div class="block pha drugH1Div" id="F228452"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Promotes initiation of fibrinolysis by binding to fibrin and converting plasminogen to plasmin. Tenecteplase is essentially alteplase with the exception of 3 point mutations and is more fibrin specific, more resistant to plasminogen activator inhibitor -1 (PAI-1), with a longer duration of action compared to alteplase. Produced by recombinant DNA technology using a mammalian cell line (Chinese hamster ovary cells).</p></div>
<div class="block phk drugH1Div" id="F228468"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub> (central compartment): 4.22 to 5.43 L; approximates plasma volume. V<sub>dss</sub>: 6.12 to 8.01 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: 90 to 130 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance: Plasma: 99 to 119 mL/minute</p></div>
<div class="block phksp drugH1Div" id="F58065158"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Body weight: Total body weight accounted for 19% variability in plasma clearance and 11% variability in V<sub>d</sub>.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58844220"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Metalyse</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-34410528">
<a name="34410528"></a>Alameh A, Jabri A, Aleyadeh W, et al. Pregnancy-associated myocardial infarction: a review of current practices and guidelines. <i>Curr Cardiol Rep</i>. 2021;23(10):142. doi:10.1007/s11886-021-01579-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/34410528/pubmed" id="34410528" target="_blank">34410528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASSENT.1">
<a name="ASSENT.1"></a>Assessment of the Safety and Efficacy of a New Treatment Strategy With Percutaneous Coronary Intervention (ASSENT-4 PCI) Investigators, "Primary Versus Tenecteplase-Facilitated Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Acute Myocardial Infarction (ASSENT-4 PCI): Randomised Trial," <i>Lancet</i>, 2006, 367(9510):569-78.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27965285">
<a name="27965285"></a>Bivard A, Huang X, McElduff P, et al. Impact of computed tomography perfusion imaging on the response to tenecteplase in ischemic stroke: analysis of 2 randomized controlled trials. <i>Circulation</i>. 2017;135(5):440-448. doi:10.1161/CIRCULATIONAHA.116.022582<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/27965285/pubmed" id="27965285" target="_blank">27965285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19092151">
<a name="19092151"></a>Böttiger BW, Arntz HR, Chamberlain DA, et al. Thrombolysis during resuscitation for out-of-hospital cardiac arrest. <i>N Engl J Med</i>. 2008;359(25):2651-2662.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/19092151/pubmed" id="19092151" target="_blank">19092151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16563599">
<a name="16563599"></a>Bozeman WP, Kleiner DM, Ferguson KL. Empiric tenecteplase is associated with increased return of spontaneous circulation and short term survival in cardiac arrest patients unresponsive to standard interventions. <i>Resuscitation</i>. 2006;69(3):399-406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/16563599/pubmed" id="16563599" target="_blank">16563599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31318627">
<a name="31318627"></a>Burgos AM, Saver JL. Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke: meta-analysis of 5 randomized trials. <i>Stroke</i>. 2019;50(8):2156-2162. doi:10.1161/STROKEAHA.119.025080<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/31318627/pubmed" id="31318627" target="_blank">31318627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32078683">
<a name="32078683"></a>Campbell BCV, Mitchell PJ, Churilov L, et al; EXTEND-IA TNK Part 2 investigators. Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: the EXTEND-IA TNK part 2 randomized clinical trial. <i>JAMA</i>. Published online February 20, 2020. doi:10.1001/jama.2020.1511<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/32078683/pubmed" id="32078683" target="_blank">32078683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29694815">
<a name="29694815"></a>Campbell BCV, Mitchell PJ, Churilov L, et al; EXTEND-IA TNK Investigators. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. <i>N Engl J Med</i>. 2018;378(17):1573-1582. doi:10.1056/NEJMoa1716405.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/29694815/pubmed" id="29694815" target="_blank">29694815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9860780">
<a name="9860780"></a>Cannon CP, Gibson CM, McCabe CH, et al. “TNK-Tissue Plasminogen Activator Compared With Front-Loaded Alteplase in Acute Myocardial Infarction. Results of the TIMI 10B Trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators,” <i>Circulation</i>, 1998, 98(25):2805-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/9860780/pubmed" id="9860780" target="_blank">9860780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15827315">
<a name="15827315"></a>De Luca G, Suryapranata H, Stone GW, et al, “Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Trials,” <i>JAMA</i>, 2005, 293(14):1759-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/15827315/pubmed" id="15827315" target="_blank">15827315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11530146">
<a name="11530146"></a>“Efficacy and Safety of Tenecteplase in Combination With Enoxaparin, Abciximab, or Unfractionated Heparin: The ASSENT-3 Randomised Trial in Acute Myocardial Infarction. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators,” <i>Lancet</i>, 2001, 358(9282):605-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/11530146/pubmed" id="11530146" target="_blank">11530146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20185783">
<a name="20185783"></a>Haley EC Jr, Thompson JL, Grotta JC, et al; Tenecteplase in Stroke Investigators. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. <i>Stroke</i>. 2010;41(4):707-711. doi:10.1161/STROKEAHA.109.572040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/20185783/pubmed" id="20185783" target="_blank">20185783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20052816">
<a name="20052816"></a>Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). <i>Reg Anesth Pain Med</i>. 2010;35(1):64-101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/20052816/pubmed" id="20052816" target="_blank">20052816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28886621">
<a name="28886621"></a>Ibanez B, James S, Agewall S, et al; ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). <i>Eur Heart J</i>. 2018;39(2):119-177. doi:10.1093/eurheartj/ehx393<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/28886621/pubmed" id="28886621" target="_blank">28886621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28191905">
<a name="28191905"></a>Ismail S, Wong C, Rajan P, Vidovich MI. ST-elevation acute myocardial infarction in pregnancy: 2016 update. <i>Clin Cardiol</i>. 2017;40(6):399-406. doi:10.1002/clc.22655<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/28191905/pubmed" id="28191905" target="_blank">28191905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23370205">
<a name="23370205"></a>Jauch EC, Saver JL, Adams HP Jr, et al, “Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association,” <i>Stroke</i>, 2013, 44(3):870-947.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/23370205/pubmed" id="23370205" target="_blank">23370205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315268">
<a name="22315268"></a>Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2)(suppl):e419S-e496S. doi: 10.1378/chest.11-2301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/22315268/pubmed" id="22315268" target="_blank">22315268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26867832">
<a name="26867832"></a>Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. <i>Chest</i>. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/26867832/pubmed" id="26867832" target="_blank">26867832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17221330">
<a name="17221330"></a>Kline JA, Hernandez-Nino J, Jones AE. Tenecteplase to treat pulmonary embolism in the emergency department. <i>J Thromb Thrombolysis</i>. 2007;23(2):101-105. doi: 10.1007/s11239-006-9018-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/17221330/pubmed" id="17221330" target="_blank">17221330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24484241">
<a name="24484241"></a>Kline JA, Nordenholz KE, Courtney DM, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. <i>J Thromb Haemost</i>. 2014;12(4):459-468. doi: 10.1111/jth.12521.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/24484241/pubmed" id="24484241" target="_blank">24484241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16488801">
<a name="16488801"></a>Keeley EC, Boura JA, and Grines CL, "Comparison of Primary and Facilitated Percutaneous Coronary Interventions for ST-Elevation Myocardial Infarction: Quantitative Review of Randomised Trials," <i>Lancet</i>, 2006, 367(9510):579-88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/16488801/pubmed" id="16488801" target="_blank">16488801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31504429">
<a name="31504429"></a>Konstantinides SV, Meyer G, Becattini C, et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>Eur Heart J</i>. 2020;41(4):543-603. doi:10.1093/eurheartj/ehz405<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/31504429/pubmed" id="31504429" target="_blank">31504429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26472998">
<a name="26472998"></a>Lavonas EJ, Drennan IR, Gabrielli A, et al. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2015;132(18)(suppl 2):S501-S518.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/26472998/pubmed" id="26472998" target="_blank">26472998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28780236">
<a name="28780236"></a>Logallo N, Novotny V, Assmus J, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. <i>Lancet Neurol</i>. 2017;16(10):781-788. doi:10.1016/S1474-4422(17)30253-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/28780236/pubmed" id="28780236" target="_blank">28780236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15744554">
<a name="15744554"></a>Melzer C, Richter C, Rogalla P, et al. Tenecteplase for the treatment of massive and submassive pulmonary embolism. <i>J Thromb Thrombolysis</i>. 2004;18(1):47-50. doi: 10.1007/s11239-004-0174-z.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/15744554/pubmed" id="15744554" target="_blank">15744554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35779553">
<a name="35779553"></a>Menon BK, Buck BH, Singh N, et al; AcT Trial Investigators. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. <i>Lancet</i>. 2022;400(10347):161-169. doi:10.1016/S0140-6736(22)01054-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/35779553/pubmed" id="35779553" target="_blank">35779553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34510263">
<a name="34510263"></a>Merlo AC, Rosa GM, Porto I. Pregnancy-related acute myocardial infarction: a review of the recent literature. <i>Clin Res Cardiol</i>. 2022;111(7):723-731. doi:10.1007/s00392-021-01937-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/34510263/pubmed" id="34510263" target="_blank">34510263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24716681">
<a name="24716681"></a>Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. <i>N Engl J Med</i>. 2014;370(15):1402-1141. doi: 10.1056/NEJMoa1302097.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/24716681/pubmed" id="24716681" target="_blank">24716681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25873823">
<a name="25873823"></a>Nobre C, Thomas B, Santos L, Tavares J. Prolonged chest compressions during cardiopulmonary resuscitation for in-hospital cardiac arrest due to acute pulmonary embolism. <i>Tex Heart Inst J</i>. 2015;42(2):136-138.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/25873823/pubmed" id="25873823" target="_blank">25873823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956226">
<a name="20956226"></a>O'Connor RE, Brady W, Brooks SC, et al, “Part 10: Acute Coronary Syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” <i>Circulation</i>, 2010, 122(18 Suppl 3):787-817.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/20956226/pubmed" id="20956226" target="_blank">20956226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACC/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(4):e362-e425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Filho.2020a">
<a name="Filho.2020a"></a>Oliveira-Filho J, Samuels OB. Approach to reperfusion therapy for acute ischemic stroke. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 3, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Filho.2020b">
<a name="Filho.2020b"></a>Oliveira-Filho J, Samuels OB. Intravenous thrombolytic therapy for acute ischemic stroke: therapeutic use. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33007077">
<a name="33007077"></a>Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.<i> Blood Adv</i>. 2020;4(19):4693-4738. doi:10.1182/bloodadvances.2020001830<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/33007077/pubmed" id="33007077" target="_blank">33007077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081529">
<a name="33081529"></a>Panchal AR, Bartos JA, Cabañas JG, et al; Adult Basic and Advanced Life Support Writing Group. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16)(suppl 2):S366-S468. doi:10.1161/CIR.0000000000000916<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/33081529/pubmed" id="33081529" target="_blank">33081529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19273826">
<a name="19273826"></a>Parsons M, Miteff F, Bateman GA, et al, “Acute Ischemic Stroke: Imaging-Guided Tenecteplase Treatment in an Extended Time Window,” <i>Neurology</i>, 2009, 72(10):915-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/19273826/pubmed" id="19273826" target="_blank">19273826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22435369">
<a name="22435369"></a>Parsons M, Spratt N, Bivard A, et al, “A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke,” <i>N Engl J Med</i>, 2012, 366(12):1099-107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/22435369/pubmed" id="22435369" target="_blank">22435369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21119096">
<a name="21119096"></a>Perrott J, Henneberry RJ, Zed PJ. Thrombolytics for cardiac arrest: case report and systematic review of controlled trials. <i>Ann Pharmacother</i>. 2010;44(12):2007-2013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/21119096/pubmed" id="21119096" target="_blank">21119096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31662037">
<a name="31662037"></a>Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2019;50(12):e344-e418. doi:10.1161/STR.0000000000000211<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/31662037/pubmed" id="31662037" target="_blank">31662037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al; ESC Scientific Document Group. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J.</i> 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10475182">
<a name="10475182"></a>“Single-Bolus Tenecteplase Compared With Front-Loaded Alteplase in Acute Myocardial Infarction: The ASSENT-2 Double-blind Randomised Trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators,” <i>Lancet</i>, 1999, 354(9180):716-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/10475182/pubmed" id="10475182" target="_blank">10475182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15199346">
<a name="15199346"></a>Sinnaeve PR, Alexander JH, Bogaerts K, et al, "Efficacy of Tenecteplase in Combination With Enoxaparin, Abciximab, or Unfractionated Heparin: One-Year Follow-Up Results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) Randomized Trial in Acute Myocardial Infarction," <i>Am Heart J</i>, 2004, 147:993-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/15199346/pubmed" id="15199346" target="_blank">15199346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34352278">
<a name="34352278"></a>Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. <i>Chest</i>. 2021;160(6):e545-e608. doi:10.1016/j.chest.2021.07.055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/34352278/pubmed" id="34352278" target="_blank">34352278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-TNKase.1">
<a name="TNKase.1"></a>TNKase (tenecteplase) [prescribing information]. South San Francisco, CA: Genentech; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-TNKaseCAN.1">
<a name="TNKaseCAN.1"></a>TNKase (tenecteplase) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Limited; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11425410">
<a name="11425410"></a>Topol EJ, GUSTO V Investigators, “Reperfusion Therapy for Acute Myocardial Infarction With Fibrinolytic Therapy or Combination Reduced Fibrinolytic Therapy and Platelet Glycoprotein IIb/IIIa Inhibition: The GUSTO V Randomized Trial,” <i>Lancet</i>, 2001, 357:1905-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/11425410/pubmed" id="11425410" target="_blank">11425410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31892636">
<a name="31892636"></a>Tsivgoulis G, Katsanos AH, Malhotra K, et al. Thrombolysis for acute ischemic stroke in the unwitnessed or extended therapeutic time window. <i>Neurology</i>. 2020;94(12):e1241-e1248. doi:10.1212/WNL.0000000000008904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/31892636/pubmed" id="31892636" target="_blank">31892636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10220625">
<a name="10220625"></a>Van de Werf F, Cannon CP, Luyten A, et al, “Safety Assessment of a Single-Bolus Administration of TNK Tissue-Plasminogen Activator in Acute Myocardial Infarction: The ASSENT-1 Trial. The ASSENT-1 Investigators,” <i>Am Heart J</i>, 1999, 137(5):786-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenecteplase-drug-information/abstract-text/10220625/pubmed" id="10220625" target="_blank">10220625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weinberg.1">
<a name="Weinberg.1"></a>Weinberg AS. Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 22, 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9955 Version 196.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
